ARS Pharmaceuticals Inc. Common Stock (SPRY)
Stock · NASDAQ · Health Care
$4.01as of 10/16/2026
Price chart
Active signals
SPRY Signal Track Record
How signals performed across all stocks →What SPRY's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 35 | +5.2% | 63% | August 14, 2026 |
| Bollinger Band Breakout | 27 | +2.1% | 56% | June 24, 2026 |
| Bollinger Band Breakdown | 17 | +7.2% | 53% | September 11, 2026 |
| 200-Day Moving Average TouchActive now | 12 | +0.3% | 50% | June 9, 2026 |
| Any 20-session window (baseline) | +2.6% | 56% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About SPRY
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 195
- Website
- ars-pharma.com/
Fundamentals
- 1-day range
- $3.81$4.08
- Market cap
- $551.13M
- P/E (trailing)
- —
- P/E (forward)
- -4.48
- EPS (trailing)
- $-2.17
- Dividend yield
- —
- Beta
- 0.91
- Avg. volume
- 1.86M
How ARS Pharmaceuticals Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 9, 2026 · via SEC EDGAR / Finnhub
Forecasts
4 analyst ratings
ARS Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- SPRYARS Pharmaceuticals Inc. Common Stock$4.02▼ 1.23%Market cap $551.13MP/E —$3.89$13.15
- STTKShattuck Labs Inc. Common Stock$5.42▼ 1.99%Market cap $549.03MP/E —$1.7$8.33
- SLNSilence Therapeutics Plc American Depository Share$8.68▼ 7.17%Market cap $548.50MP/E —$1.06$5.99
- SGMTSagimet Biosciences Inc. Series A Common Stock$8.02▼ 1.84%Market cap $539.71MP/E —$4.5$11.45
- RLMDRelmada Therapeutics Inc. Common Stock$3.1▼ 3.13%Market cap $563.26MP/E —$1.8$8
- ARVNArvinas Inc. Common Stock$6.97▼ 2.65%Market cap $567.55MP/E 50.48$6.74$14.51
- CTNMContineum Therapeutics Inc. Class A Common Stock$7.08▼ 10.38%Market cap $577.48MP/E —$7.96$17.79
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| SPRY ARS Pharmaceuticals Inc. Common Stock | $551.13M | — | $4.02 | ▼ 1.23% | $3.89$13.15 |
| STTK Shattuck Labs Inc. Common Stock | $549.03M | — | $5.42 | ▼ 1.99% | $1.7$8.33 |
| SLN Silence Therapeutics Plc American Depository Share | $548.50M | — | $8.68 | ▼ 7.17% | $1.06$5.99 |
| SGMT Sagimet Biosciences Inc. Series A Common Stock | $539.71M | — | $8.02 | ▼ 1.84% | $4.5$11.45 |
| RLMD Relmada Therapeutics Inc. Common Stock | $563.26M | — | $3.1 | ▼ 3.13% | $1.8$8 |
| ARVN Arvinas Inc. Common Stock | $567.55M | 50.48 | $6.97 | ▼ 2.65% | $6.74$14.51 |
| CTNM Contineum Therapeutics Inc. Class A Common Stock | $577.48M | — | $7.08 | ▼ 10.38% | $7.96$17.79 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Aquestive Therapeutics: The Market Is Already Pricing In Anaphylam's SuccessSeekingAlpha · 9/30/2026
Insider Activity
Insider Actions →- Casale Donn · October 1, 2026 · Grant1.04M
- Smith Margaret Ekins · September 1, 2026 · Grant1.00M
- Casale Donn · July 1, 2026 · Grant898.5K
- Kelly Michael · June 24, 2026 · Grant30.0K
- Dadoo Rajeev · June 24, 2026 · Grant30.0K
- Shah Pratik · June 24, 2026 · Grant30.0K
- Islam Saqib · June 24, 2026 · Grant30.0K
- Shawver Laura · June 24, 2026 · Grant30.0K
- Peter A. Thompson · June 24, 2026 · Grant30.0K
- RA Capital Healthcare Fund LP · June 24, 2026 · Grant30.0K
- Brent L. Saunders · June 24, 2026 · Grant30.0K
- SCHNEIDER PHILLIP M · June 24, 2026 · Grant30.0K
- Karas Eric · June 12, 2026 · Sale25.0K @ $10
- Fitzpatrick Alexander A · June 12, 2026 · Sale3.4K @ $10
- Karas Eric · June 12, 2026 · Option Exercise25.0K @ $1.5
Institutional Ownership
March 31, 2026
- Total shares held
- 92.10M
- Total value held
- $723.19M
- Institutional holders
- 196
- Unknown10.86M
- Unknown8.29M
- Unknown8.00M
- Unknown7.50M
- Unknown5.98M
- Unknown5.01M
- Unknown4.11M
- Unknown4.01M
- Unknown3.64M
- Unknown3.28M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Aquestive news highlights biotech valuation dynamics
Recent market discussion focused on Aquestive Therapeutics and the pricing of anaphylaxis drug success. While this news does not directly involve ARS Pharmaceuticals, it reflects broader sector sentiment regarding biotech valuations. ARS Pharmaceuticals is currently trading with an RSI of 37.5, indicating mild oversold conditions relative to its recent range.
Aquestive news highlights biotech valuation dynamics. Recent market discussion focused on Aquestive Therapeutics and the pricing of anaphylaxis drug success. While this news does not directly involve ARS Pharmaceuticals, it reflects broader sector sentiment regarding biotech valuations. ARS Pharmaceuticals is currently trading with an RSI of 37.5, indicating mild oversold conditions relative to its recent range.